Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients
Abstract A definitive diagnosis of Alzheimer’s disease (AD), even in the presence of co-morbid neuropathology (occurring in > 50% of AD cases), is a significant unmet medical need that has obstructed the discovery of effective AD therapeutics. An AD-biomarker, the Morphometric Imaging (MI) assay...
Main Authors: | Florin V. Chirila, Guang Xu, Dan Fontaine, Grant Kern, Tapan K. Khan, Jason Brandt, Yoshihiro Konishi, Gerhard Nebe-von-Caron, Charles L. White, Daniel L. Alkon |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-21796-y |
Similar Items
-
Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria
by: Daniela Kern, et al.
Published: (2022-03-01) -
EVEN /
by: Grant, Andrew, author
Published: (2010) -
SEVERE ALZHEIMER'S DISEASE PATIENTS SHOW SAFE AND SIGNIFICANT IMPROVEMENT IN 6 MONTH BRYOSTATIN TRIAL - IN THE ABSENCE OF MEMANTINE
by: Daniel Alkon
Published: (2023-10-01) -
Treatment with TNF‐α inhibitors versus methotrexate and the association with dementia and Alzheimer's disease
by: David M. Kern, et al.
Published: (2021-01-01) -
A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts
by: Tapan K. Khan, et al.
Published: (2009-05-01)